VRN02, DYRK1A, Autoimmune diseases

VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.

Meet the experts

Creating innovation with Harvard

Dr. Bae is in charge of Voronoi’s joint international research, including joint research in Boston with Dr. Nathanael Gray, a professor at Dana-Farber Cancer Institute and Harvard Medical School.